Share Price and Basic Stock Data
Last Updated: January 8, 2026, 6:35 am
| PEG Ratio | 3.46 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Astrazeneca Pharma India Ltd operates within the pharmaceuticals sector and has shown a robust growth trajectory in its revenue streams. For the fiscal year ending March 2025, the company recorded sales of ₹1,716 Cr, a significant increase from ₹1,296 Cr in March 2024 and ₹1,003 Cr in March 2023. The trailing twelve months (TTM) sales stood at ₹2,006 Cr, indicating a consistent upward trend. The quarterly sales figures from September 2022 to September 2023 reflect this growth, with sales rising from ₹236 Cr to ₹311 Cr, before peaking at ₹388 Cr in June 2024. Such performance suggests strong demand for Astrazeneca’s product portfolio, aligning with the broader trends in the Indian pharmaceutical industry, which has been expanding due to increasing healthcare needs and innovative product offerings.
Profitability and Efficiency Metrics
In terms of profitability, Astrazeneca Pharma India Ltd reported a net profit of ₹116 Cr for the fiscal year ending March 2025, down from ₹162 Cr in March 2024 and ₹99 Cr in March 2023. This decline in net profit is accompanied by fluctuating operating profit margins (OPM), which stood at 15% for March 2025, compared to 14% for March 2024 and 16% for March 2023. The company’s return on equity (ROE) was reported at 23.6%, while return on capital employed (ROCE) was at a commendable 33.4%, suggesting effective utilization of capital. However, the operating profit margin has shown volatility, dipping to a low of 5% in December 2023. Furthermore, the interest coverage ratio is exceptionally high at 201.78x, indicating a strong ability to cover interest expenses, reflecting operational efficiency despite the profit fluctuations.
Balance Sheet Strength and Financial Ratios
Astrazeneca’s balance sheet demonstrates a healthy financial position with total assets amounting to ₹1,518 Cr as of March 2025. The company maintains reserves of ₹794 Cr and minimal borrowings of ₹35 Cr, reflecting a low leverage ratio and financial stability. The price-to-book value (P/BV) ratio is notably high at 27.93x, indicating that the market currently values the company significantly above its book value, which may reflect investor confidence but could also imply overvaluation. The current ratio stands at 1.91, suggesting that Astrazeneca is well-equipped to meet its short-term liabilities. Moreover, the cash conversion cycle of 74 days indicates efficient management of working capital, although it has increased from prior years, which may warrant monitoring to ensure operational efficiency is maintained.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Astrazeneca Pharma India Ltd indicates a strong promoter presence, holding 75% of the shares. Foreign Institutional Investors (FIIs) hold 2.74%, while Domestic Institutional Investors (DIIs) account for 5.26%. The public shareholding stands at 17%, with a total of 32,914 shareholders recorded as of September 2025. This distribution highlights a stable ownership structure, with promoters maintaining a significant stake, which often signals confidence in the company’s future. However, the declining number of shareholders from 45,619 in December 2022 to 32,914 raises some concerns about retail investor sentiment. Despite this, the increase in DII holdings from 1.42% in December 2022 to 5.26% suggests growing institutional interest, which may bolster investor confidence in the long term.
Outlook, Risks, and Final Insight
The outlook for Astrazeneca Pharma India Ltd appears cautiously optimistic, supported by strong revenue growth and a solid balance sheet. However, the company faces risks associated with fluctuating profitability and potential market volatility. The decline in net profit and variability in operating margins may raise concerns among investors. Additionally, the high P/BV ratio could indicate vulnerability to market corrections. Nevertheless, Astrazeneca’s robust operational metrics, such as a high ROCE and low debt levels, provide a buffer against these risks. Moving forward, the company’s ability to sustain revenue growth while managing costs effectively will be critical. Investors should closely monitor profitability trends and market conditions to gauge Astrazeneca’s resilience in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,543 Cr. | 417 | 479/192 | 94.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.2 Cr. | 47.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.1 Cr. | 39.0 | 40.0/17.0 | 136 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,848.86 Cr | 1,158.96 | 53.61 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 236 | 250 | 285 | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 |
| Expenses | 195 | 213 | 225 | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 |
| Operating Profit | 41 | 37 | 60 | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 |
| OPM % | 17% | 15% | 21% | 23% | 17% | 5% | 13% | 10% | 13% | 17% | 18% | 15% | 13% |
| Other Income | 7 | 7 | -32 | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 |
| Profit before tax | 44 | 39 | 23 | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 |
| Tax % | 26% | 26% | 26% | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% |
| Net Profit | 33 | 29 | 17 | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 |
| EPS in Rs | 13.02 | 11.72 | 6.91 | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 |
Last Updated: January 2, 2026, 9:31 am
Below is a detailed analysis of the quarterly data for Astrazeneca Pharma India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 559.00 Cr.. The value appears strong and on an upward trend. It has increased from 526.00 Cr. (Jun 2025) to 559.00 Cr., marking an increase of 33.00 Cr..
- For Expenses, as of Sep 2025, the value is 484.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 445.00 Cr. (Jun 2025) to 484.00 Cr., marking an increase of 39.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 75.00 Cr.. The value appears to be declining and may need further review. It has decreased from 81.00 Cr. (Jun 2025) to 75.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 15.00% (Jun 2025) to 13.00%, marking a decrease of 2.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 11.00 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 10.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 14.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 73.00 Cr.. The value appears to be declining and may need further review. It has decreased from 75.00 Cr. (Jun 2025) to 73.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 54.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Jun 2025) to 54.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 21.69. The value appears to be declining and may need further review. It has decreased from 22.33 (Jun 2025) to 21.69, marking a decrease of 0.64.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 474 | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,006 |
| Expenses | 487 | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 1,687 |
| Operating Profit | -13 | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 320 |
| OPM % | -3% | -2% | 3% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 16% |
| Other Income | 23 | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | -3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 10 | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 46 |
| Profit before tax | 0 | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 268 |
| Tax % | 0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | ||
| Net Profit | -1 | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 199 |
| EPS in Rs | -0.20 | -8.34 | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 79.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2000.00% | 123.81% | 300.00% | 30.00% | 107.69% | 33.33% | 29.17% | -33.33% | 59.68% | 63.64% | -28.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | 2123.81% | 176.19% | -270.00% | 77.69% | -74.36% | -4.17% | -62.50% | 93.01% | 3.96% | -92.03% |
Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 16% |
| 3 Years: | 29% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 19% |
| 3 Years: | 43% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 44% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 21% |
| 3 Years: | 23% |
| Last Year: | 24% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 167 | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 794 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 35 |
| Other Liabilities | 244 | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 781 |
| Total Liabilities | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,615 |
| Fixed Assets | 94 | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 40 |
| CWIP | 9 | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 312 | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,575 |
| Total Assets | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,615 |
Below is a detailed analysis of the balance sheet data for Astrazeneca Pharma India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 794.00 Cr.. The value appears strong and on an upward trend. It has increased from 765.00 Cr. (Mar 2025) to 794.00 Cr., marking an increase of 29.00 Cr..
- For Borrowings, as of Sep 2025, the value is 35.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 36.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 781.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 712.00 Cr. (Mar 2025) to 781.00 Cr., marking an increase of 69.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,615.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,518.00 Cr. (Mar 2025) to 1,615.00 Cr., marking an increase of 97.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 64.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 24.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,575.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,454.00 Cr. (Mar 2025) to 1,575.00 Cr., marking an increase of 121.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,615.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,518.00 Cr. (Mar 2025) to 1,615.00 Cr., marking an increase of 97.00 Cr..
Notably, the Reserves (794.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -13.00 | -11.00 | 16.00 | 37.00 | 46.00 | 71.00 | 109.00 | 123.00 | 77.00 | 158.00 | 179.00 | 218.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 |
| Inventory Days | 210 | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 |
| Days Payable | 241 | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 |
| Cash Conversion Cycle | 10 | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 |
| Working Capital Days | -45 | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 |
| ROCE % | -12% | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 658,075 | 0.87 | 593.85 | 645,850 | 2025-12-08 07:42:13 | 1.89% |
| Bandhan Large & Mid Cap Fund | 96,791 | 0.68 | 87.34 | 88,791 | 2025-12-14 15:53:41 | 9.01% |
| Nippon India Pharma Fund | 62,568 | 0.67 | 56.46 | 11,561 | 2025-12-08 04:19:42 | 441.2% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 55,021 | 0.77 | 49.65 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 22,090 | 0.12 | 19.93 | N/A | N/A | N/A |
| Bandhan Aggressive Hybrid Fund | 18,833 | 1.14 | 16.99 | 18,044 | 2025-12-15 00:59:57 | 4.37% |
| Samco Flexi Cap Fund | 17,560 | 4.71 | 15.85 | 18,502 | 2025-12-14 15:53:41 | -5.09% |
| UTI MNC Fund | 15,177 | 0.48 | 13.7 | 14,461 | 2025-12-14 15:53:41 | 4.95% |
| Bandhan Large Cap Fund | 11,818 | 0.52 | 10.66 | 10,495 | 2025-12-14 11:20:50 | 12.61% |
| ICICI Prudential Smallcap Fund | 9,703 | 0.1 | 8.76 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Diluted EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Cash EPS (Rs.) | 62.29 | 70.58 | 46.22 | 31.42 | 45.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Dividend / Share (Rs.) | 32.00 | 24.00 | 16.00 | 10.00 | 2.00 |
| Revenue From Operations / Share (Rs.) | 686.52 | 518.21 | 401.19 | 322.24 | 325.42 |
| PBDIT / Share (Rs.) | 117.84 | 87.70 | 76.49 | 40.38 | 59.32 |
| PBIT / Share (Rs.) | 101.84 | 81.72 | 69.98 | 33.60 | 51.27 |
| PBT / Share (Rs.) | 62.54 | 87.82 | 53.64 | 33.22 | 50.84 |
| Net Profit / Share (Rs.) | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 |
| PBDIT Margin (%) | 17.16 | 16.92 | 19.06 | 12.52 | 18.22 |
| PBIT Margin (%) | 14.83 | 15.77 | 17.44 | 10.42 | 15.75 |
| PBT Margin (%) | 9.11 | 16.94 | 13.37 | 10.30 | 15.62 |
| Net Profit Margin (%) | 6.74 | 12.46 | 9.89 | 7.64 | 11.46 |
| Return on Networth / Equity (%) | 15.02 | 22.68 | 16.86 | 12.04 | 20.45 |
| Return on Capital Employeed (%) | 31.23 | 28.34 | 29.11 | 16.03 | 27.20 |
| Return On Assets (%) | 7.62 | 14.98 | 10.08 | 7.19 | 12.04 |
| Asset Turnover Ratio (%) | 1.32 | 1.26 | 1.09 | 0.98 | 1.10 |
| Current Ratio (X) | 1.91 | 2.61 | 2.18 | 2.12 | 2.04 |
| Quick Ratio (X) | 1.13 | 1.97 | 1.68 | 1.70 | 1.51 |
| Inventory Turnover Ratio (X) | 4.42 | 0.61 | 0.51 | 0.59 | 0.59 |
| Dividend Payout Ratio (NP) (%) | 51.84 | 24.76 | 20.14 | 8.11 | 5.35 |
| Dividend Payout Ratio (CP) (%) | 38.52 | 22.66 | 17.30 | 6.36 | 4.40 |
| Earning Retention Ratio (%) | 48.16 | 75.24 | 79.86 | 91.89 | 94.65 |
| Cash Earning Retention Ratio (%) | 61.48 | 77.34 | 82.70 | 93.64 | 95.60 |
| Interest Coverage Ratio (X) | 201.78 | 182.71 | 303.52 | 106.25 | 136.06 |
| Interest Coverage Ratio (Post Tax) (X) | 146.57 | 121.90 | 222.46 | 65.84 | 86.60 |
| Enterprise Value (Cr.) | 20979.18 | 12795.16 | 7617.77 | 5940.17 | 7173.15 |
| EV / Net Operating Revenue (X) | 12.22 | 9.88 | 7.60 | 7.37 | 8.82 |
| EV / EBITDA (X) | 71.21 | 58.36 | 39.84 | 58.85 | 48.37 |
| MarketCap / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| Retention Ratios (%) | 48.15 | 75.23 | 79.85 | 91.88 | 94.64 |
| Price / BV (X) | 27.93 | 18.68 | 13.79 | 12.49 | 16.50 |
| Price / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Astrazeneca Pharma India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Cash EPS (Rs.), as of Mar 25, the value is 62.29. This value is within the healthy range. It has decreased from 70.58 (Mar 24) to 62.29, marking a decrease of 8.29.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Dividend / Share (Rs.), as of Mar 25, the value is 32.00. This value exceeds the healthy maximum of 3. It has increased from 24.00 (Mar 24) to 32.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 686.52. It has increased from 518.21 (Mar 24) to 686.52, marking an increase of 168.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 117.84. This value is within the healthy range. It has increased from 87.70 (Mar 24) to 117.84, marking an increase of 30.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 101.84. This value is within the healthy range. It has increased from 81.72 (Mar 24) to 101.84, marking an increase of 20.12.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.54. This value is within the healthy range. It has decreased from 87.82 (Mar 24) to 62.54, marking a decrease of 25.28.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For PBDIT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has increased from 16.92 (Mar 24) to 17.16, marking an increase of 0.24.
- For PBIT Margin (%), as of Mar 25, the value is 14.83. This value is within the healthy range. It has decreased from 15.77 (Mar 24) to 14.83, marking a decrease of 0.94.
- For PBT Margin (%), as of Mar 25, the value is 9.11. This value is below the healthy minimum of 10. It has decreased from 16.94 (Mar 24) to 9.11, marking a decrease of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 6.74. This value is within the healthy range. It has decreased from 12.46 (Mar 24) to 6.74, marking a decrease of 5.72.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.02. This value is within the healthy range. It has decreased from 22.68 (Mar 24) to 15.02, marking a decrease of 7.66.
- For Return on Capital Employeed (%), as of Mar 25, the value is 31.23. This value is within the healthy range. It has increased from 28.34 (Mar 24) to 31.23, marking an increase of 2.89.
- For Return On Assets (%), as of Mar 25, the value is 7.62. This value is within the healthy range. It has decreased from 14.98 (Mar 24) to 7.62, marking a decrease of 7.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.32. It has increased from 1.26 (Mar 24) to 1.32, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.91. This value is within the healthy range. It has decreased from 2.61 (Mar 24) to 1.91, marking a decrease of 0.70.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.97 (Mar 24) to 1.13, marking a decrease of 0.84.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.42. This value is within the healthy range. It has increased from 0.61 (Mar 24) to 4.42, marking an increase of 3.81.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 51.84. This value exceeds the healthy maximum of 50. It has increased from 24.76 (Mar 24) to 51.84, marking an increase of 27.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 38.52. This value is within the healthy range. It has increased from 22.66 (Mar 24) to 38.52, marking an increase of 15.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 48.16. This value is within the healthy range. It has decreased from 75.24 (Mar 24) to 48.16, marking a decrease of 27.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 61.48. This value is within the healthy range. It has decreased from 77.34 (Mar 24) to 61.48, marking a decrease of 15.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 201.78. This value is within the healthy range. It has increased from 182.71 (Mar 24) to 201.78, marking an increase of 19.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 146.57. This value is within the healthy range. It has increased from 121.90 (Mar 24) to 146.57, marking an increase of 24.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 20,979.18. It has increased from 12,795.16 (Mar 24) to 20,979.18, marking an increase of 8,184.02.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.22. This value exceeds the healthy maximum of 3. It has increased from 9.88 (Mar 24) to 12.22, marking an increase of 2.34.
- For EV / EBITDA (X), as of Mar 25, the value is 71.21. This value exceeds the healthy maximum of 15. It has increased from 58.36 (Mar 24) to 71.21, marking an increase of 12.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For Retention Ratios (%), as of Mar 25, the value is 48.15. This value is within the healthy range. It has decreased from 75.23 (Mar 24) to 48.15, marking a decrease of 27.08.
- For Price / BV (X), as of Mar 25, the value is 27.93. This value exceeds the healthy maximum of 3. It has increased from 18.68 (Mar 24) to 27.93, marking an increase of 9.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astrazeneca Pharma India Ltd:
- Net Profit Margin: 6.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 31.23% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 146.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 91.5 (Industry average Stock P/E: 53.61)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Block N1, 12th Floor, Bengaluru Karnataka 560045 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Shilpa Divekar Nirula | Chairperson & Independent Director |
| Mr. Praveen Rao Akkinepally | Managing Director |
| Ms. Bhavana Agrawal | Executive Director |
| Ms. Sylvia Lorena Varela Ramon | Non Executive Director |
| Ms. Hooi Bien Chuah | Non Executive Director |
| Mr. Jesus Javier Diaz-Ropero Esteso | Non Executive Director |
| Ms. Revathy Ashok | Independent Director |
| Ms. Monica Widhani | Independent Director |
FAQ
What is the intrinsic value of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd's intrinsic value (as of 08 January 2026) is ₹5549.07 which is 34.44% lower the current market price of ₹8,464.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹21,161 Cr. market cap, FY2025-2026 high/low of ₹10,691/6,502, reserves of ₹794 Cr, and liabilities of ₹1,615 Cr.
What is the Market Cap of Astrazeneca Pharma India Ltd?
The Market Cap of Astrazeneca Pharma India Ltd is 21,161 Cr..
What is the current Stock Price of Astrazeneca Pharma India Ltd as on 08 January 2026?
The current stock price of Astrazeneca Pharma India Ltd as on 08 January 2026 is ₹8,464.
What is the High / Low of Astrazeneca Pharma India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astrazeneca Pharma India Ltd stocks is ₹10,691/6,502.
What is the Stock P/E of Astrazeneca Pharma India Ltd?
The Stock P/E of Astrazeneca Pharma India Ltd is 91.5.
What is the Book Value of Astrazeneca Pharma India Ltd?
The Book Value of Astrazeneca Pharma India Ltd is 320.
What is the Dividend Yield of Astrazeneca Pharma India Ltd?
The Dividend Yield of Astrazeneca Pharma India Ltd is 0.38 %.
What is the ROCE of Astrazeneca Pharma India Ltd?
The ROCE of Astrazeneca Pharma India Ltd is 33.4 %.
What is the ROE of Astrazeneca Pharma India Ltd?
The ROE of Astrazeneca Pharma India Ltd is 23.6 %.
What is the Face Value of Astrazeneca Pharma India Ltd?
The Face Value of Astrazeneca Pharma India Ltd is 2.00.